paclitaxel,cisplatin,gemcitabine
astrazeneca
[]
swog1815 disappoints after an encouraging phase 2 trial. gem/cis/nabp is not superior to gem/cis. gem/cis/durva remains 1l soc #gi23 
Hematology/Oncology fellow @EinsteinMed @MontefioreNYC via @slusom and @USJLiban. Interested in EBM & clinical reasoning. Views are my own.